Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

A Diffuse Midline Glioma Combination/Multimodality Clinical Trial and Investigation

Diffuse midline glioma (DMG) is an aggressive childhood brain tumor that is nearly always fatal. In this project, we will bring a paradigm-shifting treatment approach, which has led to cures of other previously incurable childhood cancers, to DMG for the first time: combination, multimodality therapy. Our trial will incorporate radiation, ...

Leveraging open science and collaboration to identify clinical quality ALK2 ...

Diffuse intrinsic pontine glioma (DIPG) is a rare, fatal brain cancer for which there are no good treatments.  Part of the problem is that, doing business as business is currently done, there are no financial incentives for discovering medicines for DIPG. Traditional companies see that potential for return on ...

Targeting rRNA modification and snoRNA function, a novel concept to ...

     Medulloblastoma (MB) is the most common malignant brain tumor in children. Treatment has improved survival in recent years, but patients are frequently left with devastating neurocognitive sequelae. Patients in molecular subgroups 3 and 4 still experience a high mortality rate. Our lab focuses on RNA-mediated processes to ...

Preclinical test of the proton Flash hypothesis on brain and ...

Proton radiotherapy is more effective and less toxic than X-rays, but further improvements are needed.  A recent hypothesis is that high dose rate, short duration exposure (FLASH) has fewer side-effects with equal or greater efficacy than conventional exposures.  There is evidence supporting FLASH in peripheral tissues but not ...

A novel zebrafish model of diffuse midline glioma

Abstract:  Diffuse midline glioma (DMG), previously defined as diffuse intrinsic pontine glioma (DIPG), is a highly aggressive brain tumor that appears in children and is not curable. Its cell of origin in the brain is thought to be oligodendrocytes. Current animal models involve injection of primary tumor cells, or ...

Targeting the Dysregulated Chromatin State of DIPG

How the human genome is packaged within a cell determines cell identity. This packaging, termed chromatin, is critical for dictating which genes are turned on and which are turned off. Cancer biologists have long known that defects in chromatin can change the identity of a healthy cell to make ...